These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in the elderly]. Shimamoto H; Shimamoto Y Kokyu To Junkan; 1991 Dec; 39(12):1215-20. PubMed ID: 1784847 [TBL] [Abstract][Full Text] [Related]
24. Dopamine in man: cardiorenal hemodynamics in normotensive patients with heart disease. Rosenblum R; Tai AR; Lawson D J Pharmacol Exp Ther; 1972 Nov; 183(2):256-63. PubMed ID: 5083544 [No Abstract] [Full Text] [Related]
25. [Effects of Thalamonal on the coronary circulation and cardiac efficiency]. Yusa T; Iwatsuki K Masui; 1971 May; 20(5):377-81. PubMed ID: 5103809 [No Abstract] [Full Text] [Related]
26. Whole body and regional hemodynamic effects of minoxidil in the conscious dog. Humphrey SJ; Zins GR J Cardiovasc Pharmacol; 1984; 6(6):979-88. PubMed ID: 6084789 [TBL] [Abstract][Full Text] [Related]
27. Regional blood flow changes during norepinephrine, tyramine and methoxamine infusions in the unanesthetized rhesus monkey. Hoffbrand BI; Forsyth RP J Pharmacol Exp Ther; 1973 Mar; 184(3):656-61. PubMed ID: 4631468 [No Abstract] [Full Text] [Related]
28. The comparative hemodynamic effects of isoproterenol in chronically instrumented puppies and adult dogs. Driscoll DJ; Fukushige J; Hartley CJ; Lewis RM; Entman ML Dev Pharmacol Ther; 1981; 2(2):91-103. PubMed ID: 7472110 [TBL] [Abstract][Full Text] [Related]
29. [Comparative evaluation of prostaglandins E1 and E2 in patients with hypertension]. Akhmetov MA; Elizarova NA; Davydova IA; Nekrasova AA Kardiologiia; 1986 Mar; 26(3):24-8. PubMed ID: 3520083 [TBL] [Abstract][Full Text] [Related]
30. Treatment of vasospastic disease with prostaglandin E1. Clifford PC; Martin MF; Sheddon EJ; Kirby JD; Baird RN; Dieppe PA Br Med J; 1980 Oct; 281(6247):1031-4. PubMed ID: 7427564 [TBL] [Abstract][Full Text] [Related]
31. Intra-arterial infusion of prostaglandin E1 in normal subjects and patients with peripheral arterial disease. Nielsen PE; Nielsen SL; Holstein P; Poulsen HL; Hansen EH; Lassen NA Scand J Clin Lab Invest; 1976 Nov; 36(7):633-40. PubMed ID: 1019574 [TBL] [Abstract][Full Text] [Related]
32. Prostaglandin therapy for peripheral vascular disease - better than placebo? Wennmalm A Clin Physiol; 1982 Apr; 2(2):85-7. PubMed ID: 7044659 [No Abstract] [Full Text] [Related]
34. Prostaglandin E1 (PGE1) in peripheral arteriographies. Carlson LA; Ericsson M; Erikson U Acta Radiol Diagn (Stockh); 1973 Sep; 14(5):583-7. PubMed ID: 4763571 [No Abstract] [Full Text] [Related]
35. Leg ulcer healing induced by prostaglandin E1 recorded with stereophotogrammetry. Eklund AE; Eriksson G; Olsson AG Prog Lipid Res; 1981; 20():479-84. PubMed ID: 7043482 [No Abstract] [Full Text] [Related]
36. Femoral-artery infusion of prostaglandin E 1 in severe peripheral vascular disease. Carlson LA; Eriksson I Lancet; 1973 Jan; 1(7795):155-6. PubMed ID: 4118503 [No Abstract] [Full Text] [Related]
37. Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. Mizushima Y; Yanagawa A; Hoshi K J Pharm Pharmacol; 1983 Oct; 35(10):666-7. PubMed ID: 6139437 [No Abstract] [Full Text] [Related]